Trial Profile

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 16 Oct 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Povorcitinib (Primary)
Indications Prurigo nodularis
Focus Therapeutic Use
Acronyms STOP-PN1
Sponsors Incyte Corporation

Most Recent Events

14 Oct 2025 Planned End Date changed from 2 Jun 2027 to 3 May 2027.
14 Oct 2025 Planned primary completion date changed from 25 Oct 2026 to 19 Oct 2026.
29 Jul 2025 According to Incyte Corporation media release, Phase 3 data are anticipated in 2026.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com